Ayala Pharmaceuticals' CMO departs immediately; CFO agrees to leave June 25

Ayala Pharmaceuticals, Inc.

Andres Guttierez, CMO and EVP, departed on March 25, 2024 upon closing of asset sale to Immunome.
Roy Golan, CFO, agreed to depart on June 25, 2024, per agreement dated March 27, 2024.
No replacements have been named for either departing officer.
Departures follow the previously announced Asset Purchase Agreement with Immunome, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Roy Golan

Chief Financial Officer

Ayala Pharmaceuticals, Inc.

Effective: 2024-06-25
Filed: April 3, 2024, 7:59 PM ET

the Company and Roy Golan, the Company’s Chief Financial Officer, agreed that Mr. Golan would depart the Company on June 25, 2024.

Departed

Andres Guttierez

Chief Medical Officer and Executive Vice President

Ayala Pharmaceuticals, Inc.

Effective: 2024-03-25
Filed: April 3, 2024, 7:59 PM ET

Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roy Golan departed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

the Company and Roy Golan, the Company’s Chief Financial Officer, agreed that Mr. Golan would depart the Company on June 25, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Andres Guttierez departed as Chief Medical Officer and Executive Vice President at Ayala Pharmaceuticals, Inc..

Action: departed
Role: Chief Medical Officer and Executive Vice President

Exact text from the filing

Andres Guttierez, the Company’s Chief Medical Officer and Executive Vice President, departed the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0000929638-24-001326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.